Pomerantz LLP is investigating Concentrix Corporation and some of its executives for potential securities fraud following the company's multiple earnings warnings and significant goodwill impairment charges totaling about $2.57 billion. Concentrix lowered its revenue and earnings forecasts twice in 2026, which led to a sharp decline in its stock price. The investigation aims to determine if Concentrix engaged in unlawful business practices affecting investors. Investors are advised to contact Pomerantz LLP for more information or to join a class action lawsuit.
The investigation into Concentrix Corporation provides context for technology sector activity on Pluang as of Oct 21, 2026 02:31 WIB. Among 150 priced US tech stocks, 112 rose and 38 fell. Notably, EGHT and WIT saw over 6% gains but had predominantly sell-side order activity, contrasting with BILL which also rose 6.24% and had a longer typical hold time of 80 days, highlighting diverse investor behaviors within the sector.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
